Cybin (NASDAQ:HELP) Insider Paul Glavine Purchases 100,000 Shares

Cybin Inc. (NASDAQ:HELP) insider Paul Glavine acquired 100,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was bought at an average cost of $12.47 per share, with a total value of $1,247,000.00. Following the acquisition, the insider owned 4,271,252 shares in the company, valued at $53,262,512.44. The trade was a 2.40% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Paul Glavine also recently made the following trade(s):

• On Thursday, September 3rd, Paul Glavine bought 100,000 shares of Cybin stock. The shares were purchased at an average price of $11.78 per share, for a total transaction of $1,178,000.00.
• On Monday, August 31st, Paul Glavine purchased 90,000 shares of Cybin stock. The shares were purchased at an average cost of $11.59 per share, for a total transaction of $1,043,100.00.

Cybin Price Performance

Shares of HELP stock opened at $12.97 on Friday. The company has a fifty day moving average price of $9.97 and a two-hundred day moving average price of $6.89. Cybin Inc. has a one year low of $3.76 and a one year high of $14.35. The stock has a market cap of $980.66 million, a P/E ratio of -4.29 and a beta of 0.63.

Cybin (NASDAQ:HELP) last issued its earnings results on Friday, August 14th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). As a group, equities research analysts anticipate that Cybin Inc. will post -2.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Millennium Management LLC grew its stake in shares of Cybin by 1,388.5% in the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock valued at $8,414,000 after acquiring an additional 959,448 shares in the last quarter. Pale Fire Capital SE acquired a new stake in Cybin in the 2nd quarter worth about $1,015,000. Bank of America Corp DE raised its stake in Cybin by 66.8% in the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock worth $247,000 after purchasing an additional 11,790 shares in the last quarter. AXQ Capital LP bought a new stake in Cybin in the 2nd quarter valued at about $75,000. Finally, Osaic Holdings Inc. boosted its holdings in Cybin by 46.7% in the 2nd quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock valued at $63,000 after purchasing an additional 2,400 shares during the period. 17.94% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HELP. TD Cowen raised their price objective on Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Wells Fargo & Company initiated coverage on Cybin in a report on Monday, July 27th. They set an “overweight” rating and a $16.00 target price on the stock. Finally, Wall Street Zen upgraded Cybin from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $48.60.

Cybin News Summary

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: Insider Paul Glavine bought 100,000 shares for approximately $1.25 million on September 8, increasing his direct ownership by 2.40%. Insider Eric H. L. So also purchased 100,000 shares for about $1.24 million, lifting his stake by 2.29%. These transactions follow additional purchases by both insiders in late August and early September, representing a notable pattern of open-market buying and likely supporting investor confidence. Eric So SEC filing Paul Glavine SEC filing
• Positive Sentiment: Cybin’s commercial operations are scheduled to receive investor exposure at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16. CEO Michael Halstead is expected to participate in a fireside chat, potentially providing updates on the company’s psychedelic-based mental-health drug pipeline. Morgan Stanley conference announcement
• Neutral Sentiment: Reported short interest was zero shares with a zero-day days-to-cover ratio. However, the filing also showed an invalid “NaN” percentage change, making the data unreliable as an indicator of short-selling pressure.
• Negative Sentiment: Cybin remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss of $0.91 per share was worse than the expected $0.80 loss, and analysts project a full-year loss of approximately $2.95 per share. With no new trial result or regulatory approval reported, valuation and future financing needs remain important risks after the stock’s sharp advance.

Cybin Company Profile

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.